Moreover, oncogenic mutant KRAS unleashes a plethora of signaling cascades, including rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK), and phosphoinositol 3-kinase (PI3K)/protein kinase B (AKT) pathways in various malignant entities including pancreatic cancer [11,21,22,23]. Here, KRAS is linked to pancreatic neoplasm.